Clinical Trial Update: Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dalpiciclib plus fulvestrant with pyrotinib for hormone receptor-positive, HER2-low advanced breast cancer that progressed aft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Fulvestrant (fulvestrant)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN